TY - JOUR
T1 - Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression
AU - De Berardis, Domenico
AU - Fornaro, Michele
AU - Serroni, Nicola
AU - Campanella, Daniela
AU - Rapini, Gabriella
AU - Olivieri, Luigi
AU - Srinivasan, Venkataramanujam
AU - Iasevoli, Felice
AU - Tomasetti, Carmine
AU - De Bartolomeis, Andrea
AU - Valchera, Alessandro
AU - Perna, Giampaolo
AU - Mazza, Monica
AU - Di Nicola, Marco
AU - Martinotti, Giovanni
AU - Di Giannantonio, Massimo
PY - 2015/1
Y1 - 2015/1
N2 - Agomelatine, a melatonergic antidepressant with a rapid onset of action, is one of the most recent drugs in the antidepressant category. Agomelatine's antidepressant actions are attributed to its sleep-promoting and chronobiotic actions mediated by MT1 and MT2 receptors present in the suprachiasmatic nucleus, as well as to its effects on the blockade of 5-HT2c receptors. Blockade of 5-HT2c receptors causes release of both noradrenaline and dopamine at the fronto-cortical dopaminergic and noradrenergic pathways. The combined actions of agomelatine on MT1/MT2 and 5-HT2c receptors facilitate the resynchronization of altered circadian rhythms and abnormal sleep patterns. Agomelatine appeared to be effective in treating major depression. Moreover, evidence exists that points out a possible efficacy of such drug in the treatment of bipolar depression, anxiety disorders, alcohol dependence, migraines etc. Thus, the aim of this narrative review was to elucidate current evidences on the role of agomelatine in disorders other than major depression.
AB - Agomelatine, a melatonergic antidepressant with a rapid onset of action, is one of the most recent drugs in the antidepressant category. Agomelatine's antidepressant actions are attributed to its sleep-promoting and chronobiotic actions mediated by MT1 and MT2 receptors present in the suprachiasmatic nucleus, as well as to its effects on the blockade of 5-HT2c receptors. Blockade of 5-HT2c receptors causes release of both noradrenaline and dopamine at the fronto-cortical dopaminergic and noradrenergic pathways. The combined actions of agomelatine on MT1/MT2 and 5-HT2c receptors facilitate the resynchronization of altered circadian rhythms and abnormal sleep patterns. Agomelatine appeared to be effective in treating major depression. Moreover, evidence exists that points out a possible efficacy of such drug in the treatment of bipolar depression, anxiety disorders, alcohol dependence, migraines etc. Thus, the aim of this narrative review was to elucidate current evidences on the role of agomelatine in disorders other than major depression.
KW - melatonin
KW - melatonergic receptors
KW - serotonin
KW - dopamine
KW - noradrenaline
KW - agomelatine
KW - anxiety
KW - bipolar depression
KW - seasonal affective disorder
KW - schizophrenia
KW - alcohol dependence
KW - migraines
KW - fibromyalgia
KW - psychiatric disorders
U2 - 10.3390/ijms16011111
DO - 10.3390/ijms16011111
M3 - Article
C2 - 25569089
SN - 1422-0067
VL - 16
SP - 1111
EP - 1130
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 1
ER -